[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353840-105":59,"doc-detail-353840-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","first-line-immunotherapy-for-advanced-her2-negative-gastric-cancer-differences-between-asian-and-non-asian-patients","First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients","","Emerging evidence suggests that the efficacy of immunotherapy in patients with advanced HER2-negative gastric cancer differs between Asian and non-Asian populations. This review examines potential contributors, including demographic and clinicopathologic differences, somatic mutations, molecular subtypes, tumor immunity, Helicobacter pylori infection, dietary habits, and gut microbiome composition. These factors may help predict immunotherapy response, with variability in molecular subtypes and somatic mutations linked to differences in outcomes. Differences in H. pylori infection rates and gut microbiota may shape systemic immune responses, influencing treatment results. Further mechanistic research is needed to identify biomarkers for diverse patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-line-immunotherapy-for-advanced-her2-negative-gastric-cancer-differences-between-asian-and-non-asian-patients/353840/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-line-immunotherapy-for-advanced-her2-negative-gastric-cancer-differences-between-asian-and-non-asian-patients/353840.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review focus on regarding advanced HER2-negative gastric cancer immunotherapy?","Question",{"text":112,"@type":113},"It focuses on how first-line immunotherapy efficacy and outcomes differ between Asian and non-Asian patients with advanced HER2-negative gastric cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of factors are proposed to contribute to efficacy disparities?",{"text":117,"@type":113},"The review discusses differences in demographic and clinicopathologic characteristics, somatic mutations, molecular subtypes, tumor immunity, Helicobacter pylori infection, dietary habits, and gut microbiome composition.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is further research needed according to this review?",{"text":121,"@type":113},"It emphasizes the need for mechanistic studies to explain inconsistent responses and to identify biomarkers that can predict immunotherapy benefit across diverse populations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353840,1790874370,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Cancer Biol Med 2026. doi: 10.20892/j.issn.2095-3941.2025.0398  \nREVIEW  \nFirst-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients  \nChuanhua Zhao 1, Sisi Ye 1, Meng Chen2, Jing Qian2, Jianming Xu 1  \n1The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China; 2Value & Implementation, MSD China, Shanghai 200030, China  \n\n| ABSTRACT | Emerging evidence suggests that the efficacy of immunotherapy in patients with advanced HER2-negative gastric cancer differs between Asian and non-Asian populations. This review examines potential factors contributing to these disparities, including differences in demographic and clinicopathologic characteristics, somatic mutations, molecular subtypes, tumor immunity, Helicobacter pylori (H. pylori) infection, dietary habits, and gut microbiome composition. These factors may serve as predictors of immunotherapy response in gastric cancer patients. For example, the prevalence of molecular subtypes and somatic mutations have been linked to variations in immunotherapy efficacy between Asian and non-Asian populations. In addition, differences in H. |\n| --- | --- |\n| KEYWORDS | pylori infection rates, dietary habits, and gut microbiota composition may influence systemic immune responses, and consequently, immunotherapy outcomes. Understanding the factors contributing to these disparities in immunotherapy response is crucial for optimizing treatment strategies and improving outcomes for patients with gastric cancer. Further research into the mechanisms underlying racial and ethnic disparities in immunotherapy response is needed to identify potential biomarkers predictive of immunotherapy response in diverse patient populations.\u003Cbr>Asia; gastric cancer; HER2-negative; immunotherapy |\n\nIntroduction  \nGastric cancer is a significant global health burden, ranking fifth in incidence and mortality1. Despite advances in treatment, the prognosis for advanced gastric cancer remains poor with a 5-year overall survival (OS) rate of \u003C 10% for patients with advanced disease2,3. The introduction of immunotherapy has transformed the treatment landscape for gastric cancer. Several phase 3 studies have demonstrated that the combination of chemotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, can improve the survival of patients with advanced HER2-negative gastric cancer4-8. Based on this evidence immunotherapy in combination with chemotherapy has become the standard of care for previously untreated patients with advanced HER2-negative gastric cancer9-12.  \nCorrespondence to: Jianming Xu  \n[E-mail: jmxu2003@163.com](E-mail: jmxu2003@163.com)  \nORCID ID: [https://orcid.org/0000-0003-4467-6021](https://orcid.org/0000-0003-4467-6021)  \nReceived July 21, 2025; accepted December 23, 2025;  \npublished online February 27, 2026. Available [at www.cancerbiomed.org](at www.cancerbiomed.org)  \n©2026 The Authors. Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4 .0)  \nEmerging evidence has demonstrated variability in the efficacy of immunotherapy between different patient populations, particularly Asian and non-Asian patients4,8,13-18 . However, the observed differences among Asian and nonAsian patients with advanced HER2-positive gastric cancer are inconsistent with the differences reported for patients with HER2-negative gastric cancer. The underlying factors contributing to these differences are unknown, although inherent differences in tumor characteristics between HER2-negative and-positive gastric cancers may have a role19-21. Understanding these disparities is crucial for optimizing treatment strategies and improving outcomes for all patients with gastric cancer. However, it is difficult to summarize the underlying reasons for the inconsistent outcomes of immunotherapy in different racial subgroups of patients with HER","cbCaiaCM4msPPmzM","https://ap.wps.com/l/cbCaiaCM4msPPmzM","pdf",1021656,17,"English","# Introduction\n# Global burden of gastric cancer is highest in Asia\n# Factors contributing to differences in immunotherapy efficacy\n## Demographic and clinicopathologic characteristics\n## Molecular subtypes, somatic mutations, and tumor immunity\n## Helicobacter pylori infection, dietary habits, and gut microbiome","[{\"question\":\"What does the review focus on regarding advanced HER2-negative gastric cancer immunotherapy?\",\"answer\":\"It focuses on how first-line immunotherapy efficacy and outcomes differ between Asian and non-Asian patients with advanced HER2-negative gastric cancer.\"},{\"question\":\"Which types of factors are proposed to contribute to efficacy disparities?\",\"answer\":\"The review discusses differences in demographic and clinicopathologic characteristics, somatic mutations, molecular subtypes, tumor immunity, Helicobacter pylori infection, dietary habits, and gut microbiome composition.\"},{\"question\":\"Why is further research needed according to this review?\",\"answer\":\"It emphasizes the need for mechanistic studies to explain inconsistent responses and to identify biomarkers that can predict immunotherapy benefit across diverse populations.\"}]","First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients | PDF",1790107488,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fc08df705304dfd511a24066ce17629.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/523020923cb94de784090fb1a6351795.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d29dc1515e14cfa0ed13fd9557f65177.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27d06cd6717edb00f0ba254a3e2ea22d.webp",980,1283]